Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2001-01-26
2009-11-17
Yu, Misook (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C530S327000
Reexamination Certificate
active
07619057
ABSTRACT:
The present invention discloses the identification and isolation of novel MHC class II epitopes derived from the cancer antigen, NY ESO-1. The novel MHC class II epitopes from NY-EsO-1 are recognized by CD4+T lymphocytes in an HLA class II restricted manner, in particular HLA-DR or HLA-DP restricted. The products of the gene are promising candidates for immunotherapeutic strategies for the prevention, treatment and diagnosis of patients with cancer.
REFERENCES:
patent: 5840839 (1998-11-01), Wang et al.
patent: WO 99/18206 (1999-04-01), None
patent: WO99/18206 (1999-04-01), None
patent: WO99/47641 (1999-09-01), None
patent: WO99/53938 (1999-10-01), None
patent: WO00/00824 (2000-01-01), None
patent: WO01/23560 (2001-04-01), None
patent: WO01/36453 (2001-05-01), None
Wang et al (1998, J. Immunol 161(7):3596-606).
Zeng et al. (2001, Proc. Natl. Acad. Sci. 98(7):3964-3969).
Johnstone and Thorpe (Immunochemistry in Practice, 2nd Ed. 1987, Blackwell Scientific Publications, Oxford, p. 30 and pp. 49-50).
(Khong et al., 2004, J. Immunother. 27(6):472-477) (p. 477).
Spitler (Cancer Biotherapy, 1995, 10:1-3).
Ezzell (J. NIH Res, 1995, 7:46-49).
Chaux et al, Int J Cancer, 1998, 77: 538-542.
Kirkin et al, (1998, APMIS 106:665-679).
Boon (Adv Can Res, 1992, 58:177-210).
Smith RT, 1994, Clin Immunol, 41(4): 841-849.
Roitt et al, Immunology, Fourth Edition, 1996, Mosby, p. 7.9-7.11.
Ben-Efraim, Tumor Biology 1999; 20: 1-24.
Marincola et al., TRENDS in Immunology 2003; 24: 334-341.
Frazer, I., Expert. Opin. Pharmacother. 2004; 5: 2427-2434.
Dong et al, J Immunol, 1995, 154:4536-4545.
Gebe et al, Tissue Antigens, 2002, 59:78-87.
Acsadi et al.,Nature, 352, 815-818 (1991).
Bloom et al.,J. Exp. Med., 185, 453-460 (1997).
Bowne et al.,J. Exp. Med., 190, 1717-1722 (1999).
Chaux et al.,J. Exp. Med., 189, 767-778 (1999).
Chen et al.,PNAS, 94, 1914-1918 (1997).
Chen et al.,Cancer J. Sci. Am., 5(1), 16-17 (1999).
Cooney et al.,Lancet, 337, 567-572 (1991).
Davis et al.,Hum. Gene Ther., 4, 151-159 (1993).
Eisenbraum et al.,DNA and Cell Bio., 12, 791-797 (1993).
Fuller et al.,AIDS Res. Hum. Retrovir., 10(11), 1433-1441 (1994).
Futaki et al.,Immunogenetics, 42(4), 299-301 (1995).
Fynan et al.,Proc. Natl. Acad. Sci., USA, 90, 11478-11482 (1995).
GENBANK Accession No. AF038567,Homo sapienscancer antigen-3 and cancer antigen-3-ORF2 mRNA (Jan. 16, 1999).
GENBANK Accession No. AJ223040,Homo sapiensmRNA for LAGE-1b protein (Jun. 23, 1998).
GENBANK Accession No. AJ223041,Homo sapiensmRNA for LAGE-1a protein (Jun. 23, 1998).
GENBANK Accession No. AJ223093,Homo sapiensLAGE-1 gene (Jun. 23, 1998).
GENBANK Accession No. AAB49693, gi: 1890099, autoimmunogenic cancer/testis antigen NY-ESO-1 [Home sapiens] (Dec. 22, 1999).
Gjertson et al.,Population Studies, P. Teraskai and D.W. Gjertson, editors; UCLA Tissue Typing Laboratory, LA, CA, 174-427 (1997).
Haas et al.,Am. J. Reprod.Immunuol. Microbiol., 18, 47-51 (1988).
Hara et al.,J. Exp. Med., 182, 1609-1614 (1995).
Houghton,J. Exp. Med, 180, 1-4 (1994).
Hung,J. Exp. Med., 188, 2357-2368 (1998).
Ito et al.,J. Exp. Med., 183, 2635-2644 (1996).
Jager et al.,J. Exp. Med., 187(2), 265-270 (1998).
Jager et al.,International J. Cancer, 84(5), 506-510 (1999).
Jager et al.,J. Exp. Med., 191(4), 625-630 (2000).
Kawakami et al.,J. Exp. Med., 168, 2183-2191 (1988).
Kawakami et al.,Proc. Natl. Acad. Sci., USA, 91, 3515-3519 (1994).
Kawakami et al.,Proc. Natl., Acad. Sci., USA, 91, 6458-6462 (1994).
Kawakami et al.,Imp. Adv. in Encology, 3-21 (1996).
Lee et al.,Cancer J. Sci. Am., 5(1), 20-25 (1999).
Lethe et al.,Int. J. Cancer, 76, 903-908 (1998).
Li et al.,Cancer Immunol. Immunother., 47, 32-38 (1998).
Manici et al.,J. Exp. Med., 189, 871-876 (1999).
Marchand et al.,Int. J. Cancer, 80, 219-230 (1999).
Mumberg et al.,Proc. Natl. Acad. Sci., USA, 96, 8633-8638 (1999).
Nestle et al.,Nat. Med., 4, 328-332 (1998).
Old et al.,J. Exp. Med, 187, 1163-1167 (1998).
Ossendorp et al.,J. Exp. Med., 187(5), 693-702 (1998).
Overwijk et al.,Proc. Natl. Acad. Sci., USA, 96, 2982-2987 (1999).
Pardoll et al.,Curr. Opin. Immunol., 10, 588-594 (1998).
Pieper et al.,J. Exp. Med., 189, 757-766 (1999).
Rammensee et al.,Immunogenetics, 41, 178-228 (1995).
Riley et al.,Immunity, 2, 533-543 (1995).
Robbins et al.,J. Exp. Med., 183, 1185-1192 (1995).
Rosenberg et al.,J. Immunother., 19, 81-84 (1996).
Rosenberg et al.,Immunity., 10, 281-287 (1998).
Rosenberg et al.,Nat. Med., 4, 321-327 (1998).
Sonderstrup et al.,Immunol. Rev, 164, 129-138 (1998).
Southwood et al.,J. Immunol., 160, 3363-3373 (1998).
Stockert et al.,J. Exp. Med., 187, 1349-1354 (1998).
Thurner et al.,J. Exp. Med., 190, 1669-1678 (1999).
Toes et al.,J. Exp. Med., 189, 753-756 (1999).
Topalian et al.,J. Exp. Med., 183, 1965-1971 (1996).
Touloukian et al.,J. Immunol., 164, 3535-3542 (2000).
Van Der Bruggen et al.,Science, 254, 1643-1647 (1991).
Walter et al.,N. Engl. J. Med., 333, 1038-1044 (1995).
Wang et al.,Gene, 153, 197-202 (1995).
Wang et al.,J. Exp. Med., 181, 799-804 (1995).
Wang et al.,J. Exp. Med., 184, 2207-2216 (1996).
Wang,Mol. Med., 3, 716-31 (1997).
Wang et al.,J. Immunol., 161, 3596-3606 (1998).
Wang et al.,Immunol. Rev., 170, 85-100 (1999).
Wang et al.,J. Exp. Med., 189, 1659-1667 (1999).
Wang et al.,Science, 284, 1351-1354 (1999).
Wang et al.,Trends in Immunology, 22(5), 269-276 (2001).
Weber et al.,J. Clin. Invest., 102, 1258-1264 (1998).
Williams et al.,Proc. Natl. Acad. Sci,. USA, 88, 2726-2730 (1991).
Wolff et al.,Science, 247, 1465-1468 (1990).
Yang et al.,Proc. Natl. Acad. Sci, USA, 87, 9568-9572 (1990).
Zeng et al.,J. Immunol., 165, 1153-1159 (2000).
Zeng et al.,PNAS, 98(7), 3964-3969 (2001).
Rosenberg Steven A
Wang Rong-Fu
Zeng Gang
Halvorson Mark
Leydig & Voit & Mayer
The United States of America as represented by the Secretary, De
Yu Misook
LandOfFree
MHC class II restricted T cell epitopes from the cancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with MHC class II restricted T cell epitopes from the cancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MHC class II restricted T cell epitopes from the cancer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4081202